SCHEMBL27075271

SCHEMBL27075271

COC(=O)c1nc(Br)ccc1NC(C)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
TSHR P16473 2/20 0.43
NPSR1 Q6W5P4 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
IAPP P10997 1/20 0.41
CYP1A2 P05177 2/20 0.40
MAPT P10636 5/20 0.40
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
CYP2C19 P33261 1/20 0.38
KDM4E B2RXH2 2/20 0.38
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.38
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29922567 0.85 KMT2A (0.49) ALDH1A1TSHRNPSR1CYP1A2MAPT
SCHEMBL15574689 0.85 KMT2A (0.49) ALDH1A1TSHRNPSR1CYP1A2MAPT
SCHEMBL27033930 0.82 KMT2A (0.41) ALDH1A1TSHRNPSR1CYP1A2MAPT
SCHEMBL4772581 0.81 HPGD (0.42) ALDH1A1NPSR1CYP1A2MAPTKMT2A
SCHEMBL24251808 0.79 ALDH1A1 (0.48) ALDH1A1TSHRCA1CA2CA9
SCHEMBL29756270 0.79 ALDH1A1 (0.48) ALDH1A1TSHRCA1CA2CA9
SCHEMBL29469481 0.78 KMT2A (0.48) ALDH1A1NPSR1KMT2AMEN1KDM4E
SCHEMBL22660238 0.78 KMT2A (0.48) ALDH1A1NPSR1KMT2AMEN1KDM4E
SCHEMBL388845 0.78 NPSR1 (0.50) ALDH1A1TSHRNPSR1CA1CA2
SCHEMBL29829085 0.78 NPSR1 (0.50) ALDH1A1TSHRNPSR1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600723-B2 Tetracyclic compounds as DGK inhibitors INCYTE CORPORATION (US) 2026-04-14 US disclosed
US-20240034734-A1 TETRACYCLIC COMPOUNDS AS DGK INHIBITORS INCYTE CORPORATION 2024-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034734-A1 TETRACYCLIC COMPOUNDS AS DGK INHIBITORS DGKA, DGKG, DGKI ALDH1A1 3928/4885TSHR 3374/4885NPSR1 4801/4885
US-12600723-B2 Tetracyclic compounds as DGK inhibitors DGKB, DGKA, NR2C2 ALDH1A1 3817/4885TSHR 357/4885NPSR1 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.